Alector, Inc.
NASDAQ:ALEC
1.71 (USD) • At close February 4, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Alector, Inc. |
Symbool | ALEC |
Munteenheid | USD |
Prijs | 1.71 |
Beurswaarde | 167,464,746 |
Dividendpercentage | 0% |
52-weken bereik | 1.59 - 7.577 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Arnon Rosenthal Ph.D. |
Website | https://www.alector.com |
An error occurred while fetching data.
Over Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)